Xygrel-AS Combikit contains a combination of Ticagrelor (90 mg) and Aspirin (75 mg), formulated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Ticagrelor is a reversible oral P2Y12 receptor antagonist that inhibits platelet aggregation by preventing adenosine diphosphate (ADP) from binding to its platelet receptor, thereby reducing the risk of clot formation. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation. The combination of these agents provides a dual antiplatelet effect, enhancing efficacy in reducing the incidence of cardiovascular death, myocardial infarction, and stroke compared to monotherapy. Xygrel-AS Combikit is indicated for use in patients undergoing percutaneous coronary intervention (PCI) or those with unstable angina or non-ST elevation myocardial infarction (NSTEMI). It should be used under strict medical supervision due to potential risks including bleeding complications, dyspnea, and hypersensitivity reactions. Dosage adjustments and contraindications must be carefully considered, particularly in patients with active bleeding, history of intracranial hemorrhage, or severe hepatic impairment. Regular monitoring and adherence to prescribed regimens are essential to optimize therapeutic outcomes.